HilleVax, Inc. (NASDAQ:HLVX) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC decreased its holdings in HilleVax, Inc. (NASDAQ:HLVX) by 11.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 627,669 shares of the company’s stock after selling 80,362 shares during the quarter. Geode Capital Management LLC owned about 1.26% of HilleVax worth $1,105,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Barclays PLC raised its holdings in shares of HilleVax by 255.6% in the third quarter. Barclays PLC now owns 42,033 shares of the company’s stock valued at $74,000 after buying an additional 30,213 shares during the last quarter. Zacks Investment Management increased its position in HilleVax by 411.9% in the 3rd quarter. Zacks Investment Management now owns 92,803 shares of the company’s stock valued at $163,000 after acquiring an additional 74,673 shares during the period. Jane Street Group LLC increased its position in HilleVax by 81.7% in the 3rd quarter. Jane Street Group LLC now owns 79,039 shares of the company’s stock valued at $139,000 after acquiring an additional 35,546 shares during the period. Braidwell LP purchased a new stake in HilleVax during the 3rd quarter valued at approximately $1,873,000. Finally, Verition Fund Management LLC acquired a new stake in HilleVax during the 3rd quarter worth approximately $331,000. Institutional investors and hedge funds own 86.42% of the company’s stock.

HilleVax Trading Down 2.3 %

Shares of HLVX stock opened at $2.09 on Friday. HilleVax, Inc. has a twelve month low of $1.55 and a twelve month high of $20.22. The business’s 50 day moving average is $1.94 and its two-hundred day moving average is $2.68. The company has a market capitalization of $104.09 million, a P/E ratio of -0.67 and a beta of 0.75.

HilleVax (NASDAQ:HLVX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). As a group, equities analysts predict that HilleVax, Inc. will post -2.64 earnings per share for the current fiscal year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.